Samples from patients under treatment, e.g. patient H (diagnosed with hyperornithinemia- hyperammonemia- homocitrullinuria (HHH) syndrome, also known as ornithine translocase (SLC25A15) deficiency) receiving citrulline, were difficult to diagnose since the framework cannot distinguish between abnormal biomarker values due to treatment or caused by the IMD. This evidence concerns the gene SLC25A15 and Hyperammonemia.